Neuland Laboratories (Neuland) has initiated manufacturing of peptides blocks by commercializing the production of Fmoc Pseudoproline Dipeptides and other building blocks in India and the US subsidiary.
The company said that in the initial phase, it will target the US and European markets. Developing markets will follow in the next phase.
Neuland has commissioned a new facility for manufacturing of High Potent APIs (HAPIs). The company has also reinforced its R&D resources to support its focus on development of HAPIs.
Reportedly, Neuland has identified and initiated the work in the high growth areas of Vitamin-D analogs, Oncology Nucleosides and Peptides, among other HAPIs .
Sucheth Rao Davuluri, CEO, Neuland, said: “Advances in drug delivery technologies are opening up avenues in High potent APIs (HAPIs), peptides and other niche market segments like Vitamin D analogs. Neuland sees this as a potential area for high growth, which is a synergy with both our contract research and API business. Neuland has also commissioned a new facility for the cGMP manufacturing of High Potent APIs (HAPIs) and also adding the R&D resources to support development of HAPIs.”